ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

Payout in Kangmei shareholder suit to empower Chinese investors

China's 1st securities class-action lawsuit to have lasting impact

Kangmei Pharmaceutical was one of China’s biggest publicly traded drugmakers and a stock market darling.   © Reuters

Long-suffering shareholders in debt-ridden Kangmei Pharmaceutical who lost money as a result of an 88.6 billion yuan ($13.9 billion) fraud, have moved closer to winning compensation after two court rulings over the past three weeks.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more